Since 1990, the ADCC at NYU has been providing core resources and pilot study support to a comprehensive, multidisciplinary research program on aging and AD that spans basic through psychosocial research. The main scientific goal of the ADCC is to facilitate and enhance research that will lead to early diagnosis and prevention. Over the next 5-years, core resources will be used to study the transition from normal aging to mild cognitive impairment (MCI) and early AD, and also to examine other dementia etiologies that may overlap with early AD. In addition to NYUSM, investigators at the Nathan Kline Institute (NKI), the NYS Institute for Basic Research (IBR), and other New York City area facilities are also participating. Patients with AD and related disorders, subjects with MCI, and cognitively normal subjects are studied longitudinally through postmortem. A Director and eight Associate Leaders who serve on an Executive Committee and an External Scientific Advisory Committee supervise the ADCC. Standard ADCC cores supported consist of Administrative, Clinical, Neuropathology, Data Management and Education Cores. Two additional important resources, Neuroimaging and Caregiver Cores, significantly strengthen the research contributions of the ADCC investigators. The Clinical Core includes CSF and Blood Sample Banks and a Satellite Multicultural Clinic focusing on minority recruitment. The Neuropathology Core includes a morphometry component at IBR and a satellite at the Sun Health Research Institute (Sun City, AZ). Each year, the ADC directly supports several pilot studies, and provides core resources (subjects, clinical to extensive current research receiving primary support from the NIH and other sources. There is extensive collaboration with other ADC's and national consortia, and data from the NYU ADCC is shared with the National Alzheimer's Coordinating Center (NACC) and with numerous collaborating investigators. The NYU ADCC has made and will continue to make substantial contributions toward eliminating the problem of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG008051-16
Application #
6896332
Study Section
Special Emphasis Panel (ZAG1-ZIJ-8 (J1))
Program Officer
Phelps, Creighton H
Project Start
1997-07-15
Project End
2010-04-30
Budget Start
2005-07-01
Budget End
2006-04-30
Support Year
16
Fiscal Year
2005
Total Cost
$1,663,626
Indirect Cost
Name
New York University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
de Leon, Mony J; Pirraglia, Elizabeth; Osorio, Ricardo S et al. (2018) The nonlinear relationship between cerebrospinal fluid A?42 and tau in preclinical Alzheimer's disease. PLoS One 13:e0191240
Lakshmanan, Karthik; Brown, Ryan; Madelin, Guillaume et al. (2018) An eight-channel sodium/proton coil for brain MRI at 3 T. NMR Biomed 31:
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Herline, Krystal; Prelli, Frances; Mehta, Pankaj et al. (2018) Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimers Res Ther 10:54
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872

Showing the most recent 10 out of 604 publications